NEW YORK, Oct. 25, 2022 (GLOBE NEWSWIRE) – The Rosen Law Firm, a leading global investor rights law firm, has issued a reminder for purchasers of Humanigen, Inc. (NASDAQ: HGEN) securities between May 16, 2020, and July 12, 2022 (the “Class Period”), of the critical lead plaintiff deadline on October 25, 2022.
Why This Matters: If you acquired Humanigen securities during the Class Period and have incurred losses exceeding $100,000, you may qualify for compensation without incurring any out-of-pocket expenses through a contingency fee arrangement.

Next Steps: To participate in the Humanigen class action, visit Rosen Law Firm or contact Phillip Kim, Esq. toll-free at 866-767-3653, or via email at [email protected] or [email protected]. A class action lawsuit has already been initiated, and if you wish to act as lead plaintiff, your motion must be submitted to the Court by today, October 25, 2022. A lead plaintiff represents other class members in managing the litigation.

Why Choose Rosen Law Firm: Investors are encouraged to select experienced counsel with a proven record in leadership roles within securities class actions. Some firms sending out notices may lack relevant experience and resources. Rosen Law Firm focuses on securities class actions and shareholder derivative litigation, boasting the largest settlement in a securities class action against a Chinese company. The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top four since 2013, recovering hundreds of millions of dollars for investors. In 2019 alone, they secured over $438 million in investor recoveries, and founding partner Laurence Rosen was recognized by Law360 as a Titan of the Plaintiffs’ Bar in 2020.

Case Details: The lawsuit alleges that during the Class Period, defendants made false and misleading statements and failed to disclose crucial information, including: (1) the ineffectiveness of lenzilumab in treating hospitalized COVID-19 patients; (2) the unlikelihood of FDA approval for lenzilumab’s Emergency Use Authorization (EUA); (3) the overstated clinical and commercial prospects of lenzilumab; and (4) that Humanigen’s public statements were materially false and misleading throughout the relevant time. The lawsuit contends that investors suffered damages once the truth became known.